Part 3/5:
Extrapolating this to the broader rare disease market, Winton estimates the revenue potential of cures to be around $2 billion per therapy - over 20 times more valuable than a traditional treatment. This is because cures not only eliminate the need for ongoing care, but also pull all of that future revenue forward into the present.
The Underappreciated Potential of Cures
Despite this massive value proposition, the market is currently underpricing and underappreciating the potential of curative therapies. Companies like Intellia Therapeutics, which is developing a cure for HAE, are trading at a fraction of what their asset could be worth if priced appropriately.